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Charcot-Marie-Tooth disease type 4C is the most common recessively inherited demyelinating neuropathy that results from loss of
function mutations in the SH3TC2 gene. Sh3tc2/ mice represent a well characterized disease model developing early onset
progressive peripheral neuropathy with hypo- and demyelination, slowing of nerve conduction velocities and disturbed nodal
architecture. The aim of this project was to develop a gene replacement therapy for treating Charcot-Marie-Tooth disease type
4C to rescue the phenotype of the Sh3tc2/ mouse model. We generated a lentiviral vector LV-Mpz.SH3TC2.myc to drive
expression of the human SH3TC2 cDNA under the control of the Mpz promoter speciﬁcally in myelinating Schwann cells. The
vector was delivered into 3-week-old Sh3tc2/ mice by lumbar intrathecal injection and gene expression was assessed 4–8 weeks
after injection. Immunoﬂuorescence analysis showed presence of myc-tagged human SH3TC2 in sciatic nerves and lumbar roots in
the perinuclear cytoplasm of a subset of Schwann cells, in a dotted pattern co-localizing with physiologically interacting protein
Rab11. Quantitative PCR analysis conﬁrmed SH3TC2 mRNA expression in different peripheral nervous system tissues. A treat-
ment trial was initiated in 3 weeks old randomized Sh3tc2/ littermate mice which received either the full or mock (LV-Mpz.Egfp)
vector. Behavioural analysis 8 weeks after injection showed improved motor performance in rotarod and foot grip tests in treated
Sh3tc2/ mice compared to mock vector-treated animals. Moreover, motor nerve conduction velocities were increased in treated
Sh3tc2/ mice. On a structural level, morphological analysis revealed signiﬁcant improvement in g-ratios, myelin thickness, and
ratios of demyelinated ﬁbres in lumbar roots and sciatic nerves of treated Sh3tc2/ mice. Finally, treated mice also showed
improved nodal molecular architecture and reduction of blood neuroﬁlament light levels, a clinically relevant biomarker for axonal
injury/degeneration. This study provides a proof of principle for viral gene replacement therapy targeted to Schwann cells to treat
Charcot-Marie-Tooth disease type 4C and potentially other similar demyelinating inherited neuropathies.
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Introduction
Charcot-Marie-Tooth disease type 4 (CMT4) includes sev-
eral recessively inherited demyelinating neuropathy forms
caused by mutations in different genes, which lead to loss
of function of the encoded proteins. CMT4C appears to be
the most prevalent among this overall rare group of neu-
ropathies, accounting for almost half of all CMT4 cases
(Fridman et al., 2015). Patients with CMT4C usually pre-
sent in the ﬁrst decade of life with delayed walking, pro-
gressive distal muscle atrophy and weakness, areﬂexia and
sensory loss. Almost all patients develop foot deformities
and scoliosis, often requiring surgery (Kessali et al., 1997;
Gabreels-Festen et al., 1999; Azzedine et al., 2006). Cranial
nerve involvement with severe hearing loss, slow pupillary
light reﬂexes, and lingual fasciculations are common with
phenotypic variations within families (Gooding et al., 2005;
Colomer et al., 2006; Varley et al., 2015). A combination
of proprioceptive loss and vestibular neuropathy may cause
disabling imbalance early in disease evolution (Perez-
Garrigues et al., 2014). Electrophysiological studies in
CMT4C patients conﬁrm the demyelinating process with
mean median motor nerve conduction velocity (MNCV)
of 22.6m/s. Nerve biopsies were characterized by an in-
crease of basement membranes around myelinated, demye-
linated, and unmyelinated axons, relatively few onion
bulbs, and, most typically, large cytoplasmic extensions of
Schwann cells (Kessali et al., 1997; Gabreels-Festen et al.,
1999; Senderek et al., 2003).
Linkage analysis studies and homozygosity mapping
(LeGuern et al., 1996) identiﬁed the CMT4C disease
locus on chromosome 5q32, with subsequent discovery of
several mutations in the SH3TC2/KIAA1985 gene
(Senderek et al., 2003). At least 28 different SH3TC2 mu-
tations have been described to date, mostly truncating but
also missense, with higher frequency among certain ethnic
groups (Lassuthova et al., 2011) likely due to founder ef-
fects (Gooding et al., 2005). The gene covers 62 kb of gen-
omic sequence and consists of at least 18 variably spliced
exons. SH3TC2 encodes a protein of 1288 amino acids
containing two Src homology 3 (SH3) and 10 tetratrico-
peptide repeat (TPR) domains sharing no overall signiﬁcant
similarity to any other human protein with known func-
tion. The presence of SH3 and TPR domains suggests that
SH3TC2 could act as a scaffold protein (Senderek et al.,
2003). SH3TC2 is well conserved among vertebrate species,
whereas no non-vertebrate orthologues were identiﬁed.
SH3TC2 is present in several components of the endocytic
pathway including early and late endosomes, and clathrin-
coated vesicles close to the trans-Golgi network and in the
plasma membrane. This localization is altered in CMT4C
mutants examined in vitro (Lupo et al., 2009).
A mouse model of CMT4C has been generated and stu-
died in detail by replacing exon 1 of the Sh3tc2 gene with
an enhanced GFP (eGFP)-Neo cassette (Arnaud et al.,
2009). Sh3tc2-null mice developed an early onset progres-
sive peripheral neuropathy with decreased motor and sen-
sory nerve conduction velocity and hypomyelination. Onset
of myelin pathology in sciatic nerves of Sh3tc2/ mice was
somewhere between postnatal Days 0 and 5, since at 5
days of age there was already a difference between the
mutants and controls (Arnaud et al., 2009; Gouttenoire
et al., 2013). This phenotype was progressive as demon-
strated by increasing myelin pathology and more difference
in nerve conduction velocities in mutant compared to con-
trol mice at 1 year of age as compared to 1–2 months of
age (Arnaud et al., 2009).
Murine SH3TC2 is speciﬁcally expressed in Schwann
cells and localized to the plasma membrane and to the
perinuclear endocytic recycling compartment, suggesting a
possible function in myelination and/or in regions of axo-
glial interactions. Ultrastructural analysis of myelin in the
peripheral nerve of mutant mice showed abnormal organ-
ization of the node of Ranvier, a phenotype that was con-
ﬁrmed in CMT4C patient nerve biopsies. These ﬁndings
suggested a role for the SH3TC2 gene product in myelin-
ation and in the integrity of the node of Ranvier (Arnaud
et al., 2009). SH3TC2 interacts with ERBB2 and plays a
role in the regulation of ERBB2 intracellular trafﬁcking
from the plasma membrane upon NRG1 activation while
dysregulated NRG1/ERBB signalling was found in
SH3TC2-deﬁcient Schwann cells that may account for the
disturbed axonal size sensing and the hypomyelination pre-
sent in CMT4C patients (Gouttenoire et al., 2013).
Additionally, SH3TC2 was found to be an effector of the
small GTPase Rab11, a key regulator of recycling
endosome functions. Neuropathy-causing missense
mutations in SH3TC2 disrupted this interaction
(Stendel et al., 2010), providing a likely mechanism for
the progressive nature of CMT4C neuropathy.
In summary, both the clinical phenotype and molecular
basis of CMT4C suggest loss of function of SH3TC2,
which results in early onset and slowly progressive hypo-
myelination in the peripheral nerves. Sh3tc2/ mice
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recapitulate all major aspects of the disease. We have there-
fore developed a gene replacement strategy for CMT4C
using a viral vector delivered intrathecally for Schwann
cell-speciﬁc expression of human SH3TC2 (hSH3TC2).
Treatment of Sh3tc2/ mice at the age of 3 weeks resulted
in signiﬁcant improvement of several pathological features
indicating that this approach could be further developed to
treat CMT4C patients.
Materials and methods
Cloning of lentiviral vectors
SH3TC2 cDNA was cloned into the pcDNA3 vector under the
CMV promoter (gift from Dr Vincenzo Lupo, University of
Valencia). We added the myc-tag downstream of SH3TC2
by PCR ampliﬁcation (Supplementary material). Correct local-
ization of SH3TC2.myc tag was conﬁrmed by cell transfection
into HeLa cells (Supplementary Fig. 1). The lentiviral vector
backbone originating from pCCLsin.PPT.hPGK.GFP.pre, in
which hPGK promoter was replaced by the myelin-speciﬁc
rat myelin protein zero (Mpz) promoter (Sargiannidou et al.,
2015; Kagiava et al., 2016) was used to clone the
SH3TC2.myc construct. The Gibson Assembly master mix
(NEB) was used to ligate the two fragments together. The
full vector (LV-Mpz.SH3TC2.myc) was conﬁrmed by direct
sequencing analysis (Fig. 1A). The LV-Mpz.EGFP vector, al-
ready cloned in our lab, was used as a mock vector (Fig. 1B).
Vector production
Lentiviral vectors were produced by transient co-transfection
of HEK 293T cells with transfer plasmid and helper plasmids
using the calcium phosphate co-precipitation method as
described previously (Sargiannidou et al., 2015)
(Supplementary material).
CMT4C mouse model
The generation and characterization of the Sh3tc2/ mouse
model has been described previously (Arnaud et al., 2009).
This line was kept under speciﬁc pathogen free (SPF), standard
controlled conditions of temperature (21–23C), humidity, air
exchange and light cycle (12/12 h light/dark) and provided
with standardized mouse diet and drinking water ad libitum.
All experimental procedures were conducted in accordance
with animal care protocols approved by the Cyprus
Government’s Chief Veterinary Ofﬁcer (project license CY/
EXP/PR.L3/2017) according to national law and European
guidelines (EC Directive 86/609/EEC).
Human sural nerve biopsy material
As a positive control for hSH3TC2 expression derived
from the viral vector, we used anonymized material from a
diagnostic sural nerve biopsy tissue following informed con-
sent by the patient under the Protocol ‘Translational Research-
Neurogenetics Department’ in accordance with the Declaration
of Helsinki, and approved by the National Bioethics
Committee of Cyprus (EEBK/EP/2013/28).
Intraneural and intrathecal vector
delivery
Vector delivery was performed under anaesthesia either by
direct intraneural injection (10 ml) into surgically exposed
mid-sciatic nerves of 2-month-old mice (Sargiannidou et al.,
2015), or intrathecally (30 ml) into L5–L6 intervertebral space
of 3-week-old mice (Kagiava et al., 2016, 2018; Kagiava and
Kleopa, 2018) (Supplementary material).
Vector copy number determination
The average vector copy number per cell in DNA extracted
from lumbar root and sciatic nerves was calculated as the total
vector copy number divided by the total cell number (Geraerts
et al., 2006; Christodoulou et al., 2016) (Supplementary
material).
Immunofluorescence
Mice were anaesthetized with avertin according to institution-
ally approved protocols, and then transcardially perfused with
phosphate-buffered saline (PBS) followed by fresh 4% paraf-
ormaldehyde. The lumbar spinal cord with all roots attached
as well as sciatic nerves were dissected and frozen for cryosec-
tions. Sciatic nerves were also teased into ﬁbres under a stereo-
scope. Teased ﬁbres or sections were permeabilized in cold
acetone and incubated at room temperature with a blocking
solution of 5% bovine serum albumin (BSA) containing 0.5%
Triton
TM
X for 1 h. Primary antibodies (Supplementary mater-
ial) were incubated at 4C overnight followed by appropriate
secondary antibodies at room temperature. Slides were
mounted with ﬂuorescent mounting medium (DAKO) and
images photographed under a ﬂuorescence microscope with a
digital camera using AxioVision software (Carl Zeiss
MicroImaging).
Quantiﬁcation of SH3TC2/myc expression was performed at
4 weeks post-injection in ventral root sections (n = 3 mice) and
in sciatic nerve teased ﬁbres (n = 5 mice) from ﬁve different
areas from each slide. The number of myc-positive Schwann
cells as well as the total number of cells in each picture was
counted to determine the average expression ratio.
Immunoblot analysis
Immunoblots of lumbar root and sciatic nerve lysates collected
4 weeks post-injection (Supplementary material) were incu-
bated with anti-myc (1:1000; Santa Cruz) and anti-GAPDH
(1:4000; Santa Cruz Biotechnology) primary antibodies fol-
lowed by HRP-conjugated anti-mouse or anti-rabbit secondary
antibodies (Jackson ImmunoResearch, diluted 1:3000). The
bound antibody was visualized by an enhanced chemilumines-
cence system (GE Healthcare Life Sciences).
Real-time PCR analysis of SH3TC2
expression
RNA was isolated with the Qiagen RNeasy Lipid Tissue Mini
Kit following the manufacturer’s protocol from snap-frozen
lumbar roots and sciatic nerve tissues 4 weeks after intrathecal
injection as well as from a frozen human sciatic nerve biopsy
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Figure 1 Expression analysis of LV-Mpz.SH3TC2.myc vector. Map of the LV-Mpz.SH3TC2.myc (A) and LV-Mpz.Egfp (B) transfer
plasmids used for the full and mock lentiviral vector production, respectively. Longitudinal sections of lumbar roots (C and D) and sciatic
nerves (E and F) from Sh3tc2/ mice 4 weeks following intrathecal injection with the full or mock vector, as indicated, were stained with anti-
myc (green) and anti-hSH3TC2 (red) antibodies. Sh3tc2/ mice injected with full vector show hSH3TC2 expression in the perinuclear
cytoplasm of a subset of Schwann cells co-localizing with myc immunoreactivity in lumbar roots (D) and sciatic nerve teased fibres (F). Human
SH3TC2 expression was absent from mock vector-injected tissues (C and E). Higher magnification images and separate channels of expressing
Schwann cells are shown. Cell nuclei were stained with DAPI (blue, asterisks). Scale bars = 20 mm. (G) Counts of myc-positive cells in sciatic
nerves and lumbar roots of Sh3tc2/ mice 4 weeks following intrathecal injection of full vector were on average 38  11.11% in lumbar roots
(n = 3) and 17  2.88% in sciatic nerves (n = 5 mice). (H) Vector copy numbers following intrathecal injection obtained from n = 4 Sh3tc2/
mice 4 weeks after injection were on average 0.65  0.21 in lumbar roots and 0.25  0.15 in sciatic nerves. (I) Quantitative real-time PCR
analysis of hSH3TC2 expression in lumbar roots and sciatic nerves following intrathecal injection with full vector (n = 3 mice). Fold expression
represents relative human SH3TC2 mRNA expression levels of full vector-injected compared to non-injected Sh3tc2/ mice used as a
baseline control. A human nerve sample h1355N (sural nerve biopsy) served as positive control. All samples were normalized to endogenous
control Gapdh.
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sample used as positive control and from non-injected Sh3tc2/
mouse nerves used a baseline control. After DNase treatment,
RNA was quantiﬁed by spectrophotometry and 0.5mg of RNA
was used to synthesize cDNA using TaqManTM reverse-tran-
scription reagents. Human SH3TC2 probe (Hs00226194_m1,
Applied Biosystems) was used.
Treatment trial in Sh3tc2/ mice
For the gene therapy trial, we used two groups of Sh3tc2/
mice. All animals were intrathecally injected at the age of 3
weeks. Littermate mice were randomized to either receiving the
full vector LV-Mpz.SH3TC2.myc (treatment group) or the
mock vector LV-Mpz.Egfp (lacking the Sh3tc2 gene) as control
group. Randomization was based on animal numbering after
tailing. We randomized 2:1 because more mice with full vector
injection were needed to analyse SH3TC2.myc expression by
immunostaining, immunoblot, and real-time PCR (above),
therefore more fully-treated mice were available for behav-
ioural and electrophysiological studies. However, an equal n
number was used for the morphometric analysis groups (semi-
thin sections). Mice were evaluated at the age of 11 weeks by
behavioural analysis (n = 12 mock and n = 21 full vector) and
electrophysiological testing (n = 10 mock and n = 17 full
vector), and sacriﬁced afterwards for SH3TC2 expression ana-
lysis or for quantitative morphometric analysis (n = 9–10 per
group) (Supplementary Fig. 8). All outcome evaluations were
performed by examiners blinded to the treatment condition.
Primary endpoint was considered the rescue of pathological
changes in sciatic nerves. Secondary endpoints were the im-
provement in motor conduction velocities and in behavioural
performance.
Behavioural analysis
Rotarod and foot grip tests were performed 8 weeks post-in-
jection to assess motor balance, coordination and muscle
strength as described previously (Kagiava et al., 2018)
(Supplementary material).
Electrophysiological assessment
Bilateral sciatic nerves were stimulated in anaesthetized ani-
mals at the sciatic notch and distally at the ankle via bipolar
electrodes with supramaximal square-wave pulses (5V) of
0.05ms. Compound muscle action potentials were recorded
by a bipolar electrode inserted between digits 2 and 3 of the
hind paw and latencies were measured from the stimulus arte-
fact to the onset of the negative M-wave deﬂection based on
previously described methodology (Zielasek et al., 1996).
MNCVs were calculated by dividing the distance between
the stimulating and recording electrodes by the result of sub-
tracting the distal latency from the proximal latency.
Morphometric analysis of myelination
in lumbar spinal roots and mid-sciatic
nerves
Mice were transcardially perfused with 2.5% glutaraldehyde in
0.1M phosphate buffer. The lumbar roots and sciatic nerves,
were dissected and ﬁxed overnight at 4C, then osmicated,
dehydrated, and embedded in araldite resin. Transverse semi-
thin sections (1mm) of the lumbar spinal cord with ventral
roots and mid-sciatic nerves were obtained and stained with
alkaline toluidine blue. Sections were visualized with 10 ,
20 , 40 , and 63 objective lenses and captured with a
Zeiss AxioCam HR camera. To examine the degree of abnor-
mal myelination in both groups, images visualized at 63
were used.
The g-ratios for all myelinated ﬁbres in the two treatment
groups were calculated by Image-Pro software using a custom-
made macro that detects the axons and their myelin sheath
according to colour. This macro calculates g-ratio by dividing
the average inner perimeter of the axon by the average outer
perimeter of the axon, as well as the average myelin thickness
for each myelinated ﬁbre. This analysis allowed the calculation
of g-ratios and myelin thickness. Because more pronounced
myelination deﬁcits were observed in ﬁbres 44 mm in diameter
in the original characterization of this model (Arnaud et al.,
2009), we also analysed the subset of ﬁbres 44 mm separately
in addition to the analysis of all ﬁbres 41 mm. In addition,
completely demyelinated ﬁbres (deﬁned as axons 41 mm in
diameter devoid of myelin sheath) in anterior lumbar roots
and mid-sciatic nerves were manually counted and compared
to the total ﬁbre numbers, to obtain the ratio of demyelinated
ﬁbres.
Assessment of nodal pathology
Teased sciatic nerves from wild-type (n = 2), full vector-injected
(n = 5) and mock vector-injected Sh3tc2/ mice (n = 4) were
used to measure the nodal length by directly measuring the
width of Nav1.6 immunoreactive area using Image-Pro soft-
ware. A total of 55 nodes from mock-treated and 89 nodes
from fully-treated mice, along with 18 nodes from wild-type
mice were measured and compared.
Assessment of transcriptional
changes in treated Sh3tc2/ mice
The expression of several genes previously reported to be
dysregulated in younger Sh3tc2/ mice (Arnaud et al.,
2009) was analysed in sciatic nerves and lumbar roots ﬁrst
in untreated 11-week old Sh3tc2/ compared to wild-type
littermates (Supplementary material). Subsequently the ex-
pression of the most signiﬁcantly dysregulated genes Scip,
Cdgap, Cxcl24 and Mpz was compared between full and
mock treatment groups, using quantitative PCR. Gapdh
was used as a loading control.
Measurement of blood neurofilament
light levels
Blood samples were obtained from 6- and 25-week-old wild-
type (n = 2–3 per age group) and untreated Sh3tc2/ mice
(n = 3–4 per age group), as well as from 11-week-old full
vector- or mock vector-treated Sh3tc2/ mice (n = 5–7 per
treatment group) using standard methods (Parasuraman
et al., 2010). Blood samples were collected into EDTA-contain-
ing tubes and centrifuged at 20C and 3500 rpm for 10min.
Plasma was aliquoted and stored at 80C until testing.
Plasma sample neuroﬁlament light (NfL) concentration was
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measured at UCL using a commercially available NF-Light kit
on a single molecule array (SimoaTM) HD-1 instrument
(Quanterix).
Statistical analysis
Behavioural, electrophysiological and morphometric analysis
data, as well as plasma NfL levels obtained from full or
mock vector-treated groups were compared using the Mann-
Whitney U-test. Nodal width, real time PCR results, and base-
line NfL levels were compared with two-tailed Student’s t-test
(signiﬁcance level for all comparisons, P5 0.05).
Data availability
Data supporting these ﬁndings are available upon request.
Results
The LV-Mpz.SH3TC2.myc vector
induces widespread expression of
SH3TC2 in Schwann cells
The LV-Mpz.SH3TC2.myc (full) and LV-Mpz.Egfp (mock)
plasmids (Fig. 1A and B) were successfully cloned and ver-
iﬁed by direct sequencing. Following lentiviral (LV) vector
production, the vector titres obtained ranged from
5.3  109 to 1.5  1011 vector copies/ml as determined
by quantitative PCR and ELISA. To assess expression and
cell speciﬁcity based on the Mpz promoter, vectors were
injected either intraneurally (10 ml) into exposed sciatic
nerves (Sargiannidou et al., 2015), or intrathecally (30 ml)
into the L5–L6 intervertebral space of anaesthetized mice
(Kagiava et al., 2016, 2018). The expression and distribu-
tion of SH3TC2.myc was examined 4 and 8 weeks after
vector injection of the full vector into Sh3tc2/ mice, com-
pared to non-injected or mock vector-injected animals.
Immunostaining of sciatic nerve teased ﬁbres from mice
injected intraneurally with the LV-Mpz.SH3TC2.myc
vector showed myc immunoreactivity in the perinuclear
cytoplasm of a subset of myelinating Schwann cells in dif-
ferent nerve fascicles obtained from both proximal and
distal sections of the nerve. In contrast, no myc immunor-
eactivity was detected in non-injected sciatic nerve ﬁbres
(Supplementary Fig. 2). We similarly examined the expres-
sion of myc-tagged SH3TC2 in sciatic nerve teased ﬁbres
from intrathecally-injected mice. We found perinuclear myc
immunoreactivity in a subset of myelinating Schwann cells
in spinal roots (Fig. 1C and D) and in peripheral nerves
from full vector injected but not from mock vector injected
mice, including sciatic nerve (Fig. 1E and F) and femoral
motor nerve ﬁbres (data not shown), in keeping with our
previous ﬁndings showing widespread gene expression fol-
lowing intrathecal injection (Kagiava et al., 2016). In add-
ition to immunostaining with anti-myc antibodies, we
tested several commercially available anti-SH3TC2
antibodies to conﬁrm expression of the lentiviral vector
and conﬁrmed that a rabbit antiserum (ab204334) pro-
vided speciﬁc SH3TC2 immunoreactivity as demonstrated
by immunostaining of human sural nerve biopsy sections
(Supplementary Fig. 3).
Double immunostaining for hSH3TC2 and myc tag of
lumbar root sections and sciatic nerve ﬁbres from LV-
Mpz.SH3TC2.myc intrathecally-injected Sh3tc2/ mice
conﬁrmed the co-localization of virally expressed
hSH3TC2 in the perinuclear Schwann cell cytoplasm, typ-
ically in a granular pattern, in a subset of myelinating
Schwann cells, while SH3TC2 immunoreactivity was
absent in tissues from mock-injected Sh3tc2/ mice
(Fig. 1C–F and Supplementary Fig. 4). To clarify the cell
speciﬁcity of hSH3TC2 expression in peripheral nerve tis-
sues further, we also stained sciatic nerve cross sections
from LV-Mpz.SH3TC2.myc vector intrathecally-injected
Sh3tc2/ mice with the combination of anti-SH3TC2
with anti-vimentin (ﬁbroblast marker) or with myelin
basic protein (MBP, a myelinating Schwann cell marker)
antibodies. This analysis showed that virally delivered
SH3TC2 was expressed speciﬁcally in MBP-positive myeli-
nating Schwann cells but not in vimentin-positive ﬁbro-
blasts or non-myelinating Schwann cells (Neuberger and
Cornbrooks, 1989; Walko et al., 2013) in the peripheral
nerves of injected mice (Supplementary Fig. 5).
We used immunostaining to examine the expression of
virally-delivered hSH3TC2 in relation to the recycling
endosome GTPase Rab11, which is known to associate
with SH3TC2 (Roberts et al., 2010; Stendel et al., 2010).
Immunostaining for Rab11 in untreated Sh3tc2/ mice
showed characteristic perinuclear expression, which did
not differ from the Rab11 expression pattern in wild-type
mouse nerve ﬁbres. In LV-Mpz.SH3TC2.myc-injected
Sh3tc2/ mice, virally expressed hSH3TC2 (labelled with
anti-myc) showed co-localization with Rab11 in Schwann
cells (Supplementary Fig. 6), indicating an interaction with
endogenous Rab11, in keeping with the physiological role
of SH3TC2.
Quantiﬁcation of SH3TC2 expression rates revealed by
immunostaining in Sh3tc2/ mice 4 weeks following intra-
thecal injection of LV-Mpz-SH3TC2.myc showed that
17  2.9% of myelinating Schwann cells in sciatic nerves
(n = 5 mice counted) and 38.1  11.1% in ventral lumbar
roots (n = 3 mice counted) expressed SH3TC2 (Fig. 1G).
These expression rates corresponded to a proximal to
distal gradient of vector biodistribution following intra-
thecal injection as assessed by higher vector copy numbers
in lumbar roots (0.65  0.21) compared to sciatic nerve
(0.25  0.15) samples (Fig. 1H).
Expression of myc-tagged hSH3TC2 was also shown by
immunoblot analysis using the anti-myc antibody in sci-
atic nerve and lumbar root lysates obtained 4 weeks fol-
lowing intrathecal injection of the LV-Mpz.SH3TC2.myc
vector. The predicted protein band at 144 kDa was de-
tectable in sciatic nerves as well as in lumbar roots in two
of the three mice examined compared to a negative
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control (Supplementary Fig. 7). Finally, hSH3TC2 expres-
sion was also assessed by quantitative PCR analysis. The
SH3TC2 transcript was detected in most sciatic nerve
samples from either intraneurally (Supplementary Fig.
2E) or intrathecally-injected mice, as well as in lumbar
root samples from intrathecally-injected animals
(Fig. 1I), at levels that were below that of an adult
human sural nerve.
Gene replacement treatment in
Sh3tc2/ mice leads to improved
motor performance and nerve
function
After establishing an efﬁcient gene replacement method
for SH3TC2, we proceeded with a randomized, mock
vector-controlled, blinded treatment trial by intrathecal
injection in groups of Sh3tc2/ littermate mice at 3
weeks of age, at early stages of neuropathy. Following
injections, mice were observed for 8 weeks and then
examined for possible phenotype rescue using behavioural,
electrophysiological and histological methods at 11 weeks
of age (Supplementary Fig. 8). Results were then
compared between groups treated with the full
(LV-Mpz.SH3TC2.myc) as opposed to the mock (LV-
Mpz.Egfp) vectors. All behavioural and electrophysiological
studies were performed by examiners blinded to the treat-
ment status.
Rotarod analysis performed as described recently
(Kagiava et al., 2018) 8 weeks after injection showed that
at a speed of 20 rpm, fully-treated mice (n = 21) remained
on the rotarod signiﬁcantly longer (408.8  37.3 s) than
mock-injected mice (253.9  65 s; P = 0.024; n = 12).
Likewise, at 32 rpm, fully-treated mice remained on the
rotarod signiﬁcantly longer than mock-treated littermates
(full: 207.7  33.4 s; mock: 91.3  17.5 s; P = 0.01;
Mann-Whitney U-test) (Fig. 2A and B). Furthermore, the
foot grip test, which evaluates hind limb strength by using
an equipment that automatically measures the grams of
force required to pry the mouse from the handle, revealed
that fully-treated mice (n = 23) applied signiﬁcantly greater
force than mock-treated mice (n = 12) (full: 91.4  17 g;
compared to mock: 62.2  21 g; P = 0.0067; Mann-
Whitney U-test) (Fig. 2C). However, the motor perform-
ance of treated Sh3tc2/ remained below the indicative
levels of wild-type littermate mice.
MNCV were measured in sciatic nerves according to pre-
viously published methods (Zielasek et al., 1996). The
mean MNCV in the fully-treated Sh3tc2/ mice
(32.43  4.36m/s; n = 17 mice) was signiﬁcantly faster
than that in the mock-treated group (25.72  4.29m/s;
n = 10 mice) (P = 0.0067; Mann-Whitney U-test), but re-
mained slower than that of wild-type mice
(41.7  2.89m/s; n = 3 mice) (Fig. 2D). Thus, both motor
behavioural tests, as well as nerve conduction studies indi-
cate a signiﬁcant, albeit partial, therapeutic beneﬁt in
Sh3tc2/ mice treated with the LV-Mpz.SH3TC2.myc
than mock vector-treated littermates.
Improvement of peripheral
myelination in treated Sh3tc2/ mice
To examine whether SH3TC2 gene replacement can im-
prove the hypo- and demyelination that characterizes
Sh3tc2/ mice further, we performed morphological
analysis of anterior lumbar roots and mid-sciatic nerves
comparing treated (n = 9) and mock-treated (n = 10)
Sh3tc2/ mice 8 weeks after vector injection, at 11
weeks of age. All morphometric analysis was performed
blinded to the treatment status.
For quantitative analysis of myelination, we measured the
g-ratios as well as the average myelin thickness of all mye-
linated ﬁbres with diameter 41 mm in toluidine blue
stained transverse semithin sections (1 mm) using Image-
Pro software. Because more pronounced myelination def-
icits were observed in ﬁbres 44 mm in diameter in this
model (Arnaud et al., 2009), we also analysed the subset
of ﬁbres 44 mm separately in addition to the analysis of all
Figure 2 Behavioural and electrophysiological analysis of
treated Sh3tc2/ mice. Improved rotarod motor performance
was observed at two different speeds tested, 20 rpm (A) and 32 rpm
(B), in full vector-injected Sh3tc2/ mice (n = 21) compared to
mock vector-treated mice (n = 12), as well as an increase in foot grip
force generated in full (n = 23) compared to mock (n = 12) groups
(C). Results of MNCV of mock and full vector-treated mice 8 weeks
after vector injection are shown in D. Full vector-treated mice
(n = 17) show significantly increased MNCV compared to the mock
group (n = 10) (Mann-Whitney U-test used for all comparisons).
Results from behavioural testing and MNCV measurements in wild-
type (WT) littermate mice (n = 2–3) are included in all diagrams,
indicating that response to treatment in Sh3tc2/ mice was partial.
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ﬁbres. Our morphological analysis conﬁrmed a signiﬁcant
improvement in g-ratios, myelin thickness and ratios of
demyelinated ﬁbres in anterior lumbar roots and mid-sciatic
nerves of fully-treated compared to mock-treated Sh3tc2/
mice. In ventral lumbar roots (Fig. 3), g-ratios of all myelin-
ated ﬁbres in mock-treated mice were 0.703  0.028 as com-
pared to 0.637  0.027 in fully-treated mice (P = 0.00052;
Mann-Whitney U-test). In the subset of ﬁbres 44 mm in
diameter, the mock-treated group had a g-ratio of
0.762  0.042 and the treated group 0.705  0.038
(P = 0.015). Average myelin thickness in mock-treated
group was 0.766  0.16 mm and in fully-treated
1.053  0.28 mm (P = 0.03), while in the subset of ﬁbres
44 mm the myelin thickness was 0.758  0.14 mm in the
mock group and 1.185  0.28 mm in the treated group
(P = 0.0048).
In the sciatic nerves (Fig. 4), the average g-ratio of all mye-
linated ﬁbres in the mock-treated group was 0.673  0.034
and in the fully-treated group 0.593  0.033 (P = 0.0009),
whereas for ﬁbres 44mm g-ratio was 0.725  0.051 in the
mock and 0.638  0.046 in the treated group (P = 0.0048).
Myelin thickness of all size ﬁbres was increased in treated
mice (1.234  0.407mm) compared to the mock group
(0.899  0.311mm), an increase that did not reach statistical
signiﬁcance (P4 0.05). However, in the larger diameter
ﬁbres (44 mm) of fully-treated mice there was a signiﬁcant
increase in myelin thickness (1.410  0.376mm) compared to
the mock group (0.986  0.344mm) (P = 0.03).
Finally, the ratios of completely demyelinated ﬁbres in
both the anterior lumbar roots and in the sciatic nerves
were signiﬁcantly decreased in the fully-treated compared
to the mock-treated mice (Figs 3I and 4I). Similar to the
original observation (Arnaud et al., 2009), we did not ob-
serve any axonal loss or any inﬂammatory cells in PNS
tissues of Sh3tc2/ mice at 11 weeks of age, regardless
of treatment condition. Moreover, we could not ﬁnd any
myelination defects in lumbar spinal cord ﬁbres (data not
shown) in keeping with lack of any CNS myelination de-
fects in this model based on previous examination of
the optic nerve (Arnaud et al., 2009). Thus, LV-
Mpz.SH3TC2.myc-treated mice show signiﬁcant improve-
ment of myelination in peripheral nervous system tissues
compared to mock-treated littermates.
Improvement of nodal pathological
changes in treated Sh3tc2/ mice
Since nodal abnormalities consisting of nodal widening
have been detected as early as 1 month of age in
Sh3tc2/ mice and in biopsied nerves from CMT4C pa-
tients (Arnaud et al., 2009), we also examined nodal path-
ology to clarify whether gene replacement could reverse
some of these early onset pathological features of
CMT4C. Morphometric analysis was performed in prepar-
ations of sciatic nerve teased ﬁbres that were
immunostained for nodal marker Nav1.6, as well as for
paranodal Caspr (CNTNAP1) and juxtaparanodal Kv1.1
(KCNA1) or Caspr2 (CNTNAP2). We found that the char-
acteristic nodal widening present in nerve ﬁbres from
mock-treated animals was reduced and approached the
wild-type appearance in nerve ﬁbres of fully-treated
Sh3tc2/ mice with SH3TC2 expression (Fig. 5A–E and
Supplementary Fig. 9). We assessed the nodal length by
directly measuring the width of Nav1.6 immunoreactive
area. Quantiﬁcation of 55 nodes from n = 4 mock-treated
and 89 nodes from n = 5 fully-treated Sh3tc2/ mice,
along with 18 nodes from n = 2 wild-type mice conﬁrmed
these observations (Fig. 5F). Thus, this early characteristic
nodal abnormality that occurs in the absence of SH3TC2
can also be rescued by the gene therapy.
Transcriptional changes in Sh3tc2/
mice
Several genes involved in myelination have been found to
be downregulated in 4-week-old Sh3tc2/ mice (Arnaud
et al., 2009) with simultaneous upregulation of transcrip-
tion factors and other genes implicated in cell signalling
and adhesion processes. These ﬁndings indicate that mul-
tiple genes and cellular pathways may play a role in
CMT4C pathogenesis. Therefore, we examined whether
SH3TC2 gene replacement could rescue some of these
gene expression abnormalities. First, we examined the ex-
pression levels in lumbar roots as well as in sciatic nerves of
selected dysregulated genes comparing 11-week-old
Sh3tc2/ mice with wild-type littermates. Several of these
genes were upregulated in the sciatic nerves more than in
the lumbar roots of Sh3tc2/ mice compared to wild-type
littermates, although mostly not at the same magnitude as
reported at 4 weeks of age. Among the genes examined, the
most prominent upregulation was found for Scip/Oct-6
(Pou3f1) expression, while we also found that Mpz expres-
sion was downregulated (Supplementary Fig. 10A). We
then selected some of the most dysregulated genes at this
age in Sh3tc2/ mice, and performed a comparison of
fully-treated versus mock-treated animals (n = 4 mice per
group). This analysis showed a trend for ameliorated over-
expression of dysregulated genes in both lumbar roots and
sciatic nerves from treated mice, including Pou3f1/Scip,
Cdgap, and Cxcl14, but only Pou3f1/Scip downregulation
in the sciatic nerves was statistically signiﬁcant
(Supplementary Fig. 10B and C).
Blood neurofilament light levels as
biomarkers
Finally, in a small group of full or mock vector-treated
Sh3tc2/ mice (n = 5–7 mice per group), we measured
blood NfL levels, an established biomarker for axonal
injury/degeneration found to be elevated in sera from
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Figure 3 Morphometric analysis of anterior lumbar roots. Representative low (A and B) and higher magnification (C and D) images of
toluidine blue-stained semithin sections from anterior lumbar spinal roots of 11-week-old mock- (A and C) and full vector- (B and D) treated
Sh3tc2/ mice. Mock-injected mice show thin myelin sheaths in most of the axons as well as some completely demyelinated fibers (asterisks in C
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CMT patients including two patients with CMT4C
(Sandelius et al., 2018). We ﬁrst conﬁrmed that serum
NfL levels were elevated in Sh3tc2/ compared to
Sh3tc2+ / + littermate mice starting at 6 weeks of age and
showing progressive elevation at 25 weeks of age (Fig. 6A).
In treatment groups, mock-treated Sh3tc2/ mice at the
age of 11 weeks showed an average NfL concentration of
491  87 pg/ml (range: 348–814), while NfL concentration
in full vector-treated Sh3tc2/ mice was signiﬁcantly lower
289  18 pg/ml (range: 240–340; P = 0.022; Mann-
Whitney U-test) (Fig. 6B). Thus, this emerging blood bio-
marker shows a treatment response in the CMT4C model.
Discussion
In this study, we demonstrate that a viral vector allowing
for Schwann cell-targeted expression of hSH3TC2 could
provide a gene therapy approach for CMT4C. Delivery
of this vector into Sh3tc2/ mice, an authentic genetic
model of CMT4C, achieved Schwann cell-speciﬁc expres-
sion that was widespread after intrathecal injection. An
early treatment trial comparing LV-Mpz.SH3TC2myc-trea-
ted with mock vector-treated Sh3tc2/ mice demonstrated
signiﬁcant phenotype rescue, as indicated by improved
motor behavioural tests, increased motor conduction velo-
cities, reduction of myelin pathology and restoration of
lengthened nodal architecture in Sh3tc2/ mice. Thus,
our study provides a ﬁrst proof of principle for viral gene
replacement therapy targeted to Schwann cells to treat
CMT4C.
Like other demyelinating neuropathies, CMT4C results
from mutations in a Schwann cell-speciﬁc gene. Indeed
the initial characterization of endogenous SH3TC2 expres-
sion in mice revealed high expression speciﬁcally in sciatic
nerves, localized to Schwann cells (Arnaud et al., 2009),
indicating a cell-autonomous loss of function mechanism
underlying CMT4C neuropathy. Therefore, a targeted re-
placement of SH3TC2 in myelinating Schwann cells will be
ultimately necessary to treat CMT4C. Based on our previ-
ously-tested lentiviral vector with demonstrated Schwann
cell tropism showing high infection rates in Schwann
cells, as well as the rat Mpz promoter, which drives gene
expression restricted to myelinating Schwann cells
(Sargiannidou et al., 2015; Kagiava et al., 2016), we de-
veloped a novel vector to deliver the human SH3TC2 gene
into Schwann cells. Cell-speciﬁc expression of SH3TC2 was
shown with immunostaining in combination with cell
markers, as well as by immunoblot analysis and by detec-
tion of the transcript at the RNA level. Moreover, we could
detect the characteristic vesicular pattern of SH3TC2
immunoreactivity at the plasma membrane and in peri-
nuclear Schwann cell cytoplasm characteristic of the endo-
cytic recycling compartment, as well as co-localization with
the interacting protein Rab11 (Ullrich et al., 1996; Arnaud
et al., 2009; Stendel et al., 2010), suggesting that it assumes
the functional role of the endogenous mouse SH3TC2.
The overall vector copy numbers and gene expression
rates and levels achieved were not high, as only a subset
of Schwann cells was found to be positive for SH3TC2/myc
immunoreactivity. This is in line with the fact that we only
achieved a partial phenotype rescue as demonstrated by all
outcome measures. In other studies we also found that
similar expression rates and lower than physiological ex-
pression levels of the neuropathy-associated gene such as
GJB1 (connexin 32) were still adequate to provide a sig-
niﬁcant therapeutic beneﬁt in disease models, although not
a complete rescue (Kagiava et al., 2016, 2018). Moreover,
lower correction rates in vivo were shown to provide thera-
peutic beneﬁt in gene editing studies for muscular dystro-
phy (Long et al., 2014), overall indicating that a
therapeutic beneﬁt can be achieved even with suboptimal
gene replacement.
The Sh3tc2/ mouse provides a relevant model of
CMT4C as it recapitulates all major phenotypic features
of the disease. Although motor behavioural studies were
not previously performed at baseline in this model, we
used both rotarod analysis and foot grip tests, which are
sensitive for peripheral nerve dysfunction as shown in our
previous studies (Kagiava et al., 2016; Kagiava et al., 2018)
and in other models of demyelinating neuropathy (Zhao
et al., 2018). Both of these tests were sensitive enough to
demonstrate a signiﬁcant improvement in the treated com-
pared to the mock-treated group. In keeping with these
motor behavioural improvements, we also found that
motor nerve conduction velocities were increased in treated
Sh3tc2/ mice. In the initial characterization of this model,
at the age of 10–12 weeks, corresponding to the age of our
treatment outcome evaluation, average MNCV were
10m/s slower compared to the wild-type average
(Arnaud et al., 2009). In our groups, treated Sh3tc2/
mice were 9.3m/s slower than the wild-type average,
but 6.7m/s faster and signiﬁcantly improved than mock-
treated littermates.
Detailed morphometric analysis of myelinated ﬁbres in
spinal motor roots and mid-sciatic nerves demonstrated
Figure 3 Continued
and D), whereas full vector-injected mice show improvement of this myelin pathology. The scatter plots below display as indicated g-ratios (E) and
myelin thickness (G) of individual axons versus axonal diameter (red points: full treatment group; light blue points: mock-treated group). Each
point corresponds to one fibre. Comparison of g-ratios from all fibres, as well as from the subset of fibres44 mm (F) shows significant reduction
in fully-treated (n = 9) compared to mock treated mice (n = 10), while the corresponding myelin thickness (H) is increased. The ratio of
completely demyelinated fibres is also reduced in fully-treated compared to mock-treated Sh3tc2/ mice (I) (P-values obtained with the Mann-
Whitney U-test). Scale bars = 20 mm (A and B), 2 mm (C and D).
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Figure 4 Morphometric analysis of mid-sciatic nerves. Representative low (A and B) and higher magnification (C and D) semithin
sections from mid-sciatic nerves of 11-week-old mock- (A and C) and full vector- (B and D) treated Sh3tc2/ mice. Mock-injected mice show
thin myelin sheaths in most of the axons as well as some completely demyelinated fibres (asterisks in C and D), and these abnormalities are
ameliorated in full vector injected mice. The scatter plots below display as indicated g-ratios (E) and myelin thickness (G) of individual axons
versus axonal diameter (red points: full mice; light blue points: mock treated mice). Average g-ratios from all fibres, as well as from the subset of
fibres44mm are shown in F, and corresponding average myelin thickness in H, demonstrating significant improvement of both parameters in full
vector-treated (n = 9) compared to mock-treated mice (n = 10). There is also significant reduction of the ratio of completely demyelinated fibres
in full vector-treated animals (I) (all P-values obtained with the Mann Whitney U-test). Scale bars = 20 mm (A and B), 2 mm (C and D).
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an improvement in myelination assessed by g-ratio calcu-
lation as well as by direct average myelin thickness meas-
urements. Hypomyelination was documented in Sh3tc2/
mice as early as postnatal Day 5, becoming progressively
worse at later ages (Arnaud et al., 2009). This indicates
that the neuropathy in this model and in CMT4C results
from a combination of developmental and progressive
hypomyelination. This is in line with the putative function
of SH3TC2 in myelin biogenesis and maintenance, based
on the regulation of cargo transport, including myelin pro-
teins, through the recycling endosome (Ang et al., 2004;
Trajkovic et al., 2006; Winterstein et al., 2008). We ana-
lysed mice at the age of 11 weeks at which a marked mye-
lination defect was apparent and found a signiﬁcant
reduction of g-ratios along with increased myelin thickness
in treated mice. The morphological improvements follow-
ing gene therapy were only partial, likely reﬂecting the fact
that only a subset of myelinating Schwann cells expressed
SH3TC2. However, it is notable that even early onset
pathological changes can be improved following treatment.
Since we treated mice already at 3 weeks of age, it remains
to be shown whether treatment at a later time point, could
also provide a therapeutic beneﬁt.
In this regard, the observed improvement in the abnorm-
alities of nodal architecture is particularly interesting. The
elongation of nodes of Ranvier observed in CMT4C nerve
biopsies as well as in the Sh3tc2/ mouse present already
at early developmental stages (Arnaud et al., 2009) likely
contributes to the functional impairment and progression of
neuropathy. The cause of this abnormality is unclear. A
dual mechanism drives the formation of the nodes of
Ranvier and clustering of sodium channels during develop-
ment, consisting of the nodal adhesion system of neurofas-
cin186/NrCAM and gliomedin, as well as of the paranodal
axon-glial junctions formed by Caspr/Contactin-NF155
that restrict the lateral diffusion of nodal sodium channels
(Feinberg et al., 2010; Amor et al., 2014). Given that
Nav1.6 channels remain clustered within the elongated
nodes (Arnaud et al., 2009) and our own observations),
the elongation of the nodes in CMT4C is likely to result
from defects in lateral growth of Schwann cells during de-
velopment, making the second mechanism less efﬁcient.
Interestingly, these defects appear to be reversible, since
Figure 5 Improvement of nodal phenotype in treated Sh3tc2/ mice. Immunostaining of sciatic nerve teased fibres from mock (A) or
full vector (B) treated Sh3tc2/ mice shows expression of myc-tagged SH3TC2 (green) only in treated fibres (open arrowheads in B) around the
Schwann cell nucleus (asterisks) and the normal appearance of Nav1.6 (red)-labelled adjacent node in the fibre from fully-treated mouse (B) in
contrast to the elongated Nav1.6-labelled node in the fibre from mock-treated mouse (A) (nodal areas indicated by arrows). (C and D) High
magnification images of longitudinal sciatic nerve semithin sections from mock-injected (C) or full-vector injected (D) Sh3tc2/ mice demon-
strate the nodal elongation (C), which improves after treatment (D). (E) Staining of sciatic nerve fibres from Sh3tc2+ / + (wild-type, WT), as well
as mock-treated and full vector-treated Sh3tc2/ mice with Nav1.6 (red) nodal marker shows the typical elongation of nodal width (indicated by
white lines) in mock-treated Sh3tc2/ mice, which is improved in full vector-treated Sh3tc2/ mice nearing the appearance of Sh3tc2+ / + nodal
areas, consistent with improved nodal molecular architecture. (F) Results of quantification of 55 nodes from n = 4 mock-treated and 89 nodes
from n = 5 full vector-treated Sh3tc2/ mice, along with 18 nodes from n = 2 wild-type mice, confirm significant improvement of nodal elongation
measured by Nav1.6 staining (Mann-Whitney U-test). Scale bars = 2mm (C and D), 10mm (E).
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we observed a signiﬁcant remodelling of nodal architecture
approaching the structure of wild-type nodes in treated
compared to mock-treated mice. This may actually be a
more responsive therapeutic outcome compared to the
myelin thickness at the internode, accounting for the func-
tional improvements observed in our study.
Dysregulation of several genes associated with various
cellular functions, such as transcription factors regulating
Schwann cell maturation, signalling, adhesion, immunity,
extracellular matrix and myelination have been reported
in 4-week-old Sh3tc2/ mice (Arnaud et al., 2009).
We conﬁrmed that several of these genes were upregulated
in the sciatic nerves more that in the lumbar roots of
Sh3tc2/ mice compared to wild-type littermates at 11
weeks of age, although to a lesser degree that reported at
4 weeks, suggesting that transcriptional abnormalities are
more pronounced during development and persist in adult-
hood. We found signiﬁcant improvement only of Scip/Oct-
6 (Pou3f1) dysregulation in sciatic nerves of treated mice,
while other genes showed a non-signiﬁcant trend for nor-
malization. This result may be explained by the fact that
we only achieved a partial expression and pathology rescue
based on the other outcome measures used, as well as due
to smaller degree of transcriptional changes at this age
compared to 4 weeks of age, making a therapeutic response
more difﬁcult to demonstrate. Scip/Oct-6 plays a crucial
role in the regulation of promyelinating Schwann cell mat-
uration before axonal wrapping (Bermingham et al., 1996)
and appears to be a sensitive marker in hypomyelinating
and demyelinating neuropathies, correlating with the over-
all reduction of promyelinating Schwann cells after
SH3TC2 replacement. In a recent treatment trial in
models of CMT1A, Scip/Oct-6 was also most prominently
upregulated at baseline and was the most responsive to the
therapeutic intervention (Zhao et al., 2018).
Lastly, we demonstrate for the ﬁrst time that a clinically
relevant biomarker, plasma NfL concentration, previously
shown to be elevated in CMT patients including two cases
with CMT4C, correlating with clinical severity (Sandelius
et al., 2018), is also progressively elevated in Sh3tc2/
mice and shows a signiﬁcant improvement following gene
replacement therapy. Thus, plasma NfL level appears to be
a clinically relevant and treatment-responsive biomarker in
the CMT4C model that can be useful in future preclinical
and clinical studies.
Several challenges remain in the path to developing a
clinically translatable gene therapy for CMT4C. In the cur-
rent study, we tested the efﬁcacy of intrathecal genes as
early as possible, at 3 weeks of age. However, we also
need to demonstrate that treatment at later stages after
the onset of neuropathy can provide a similar therapeutic
beneﬁt. This question is relevant to treating CMT4C pa-
tients with a long disease course and likely ensuing second-
ary axonal loss, which is not present in the mouse model.
Nevertheless, given that this is an early onset hypomyelinat-
ing neuropathy, even early intervention provides a proof of
principle that abnormalities of myelin biogenesis and main-
tenance may be reversible, as shown by the rescue of the
early nodal elongation and hypomyelination.
Furthermore, better vector biodistribution and higher
gene expression levels are likely to provide a more robust
therapeutic response. Alternative vectors such as AAV9 or
AAVrh10 (Foust et al., 2009; Tanguy et al., 2015; Gurda
et al., 2016) could be tried if they can target Schwann cells
as well as the lentiviral vector. They offer the advantage of
improved safety with in vivo delivery because they do not
integrate into the host genome and show low immunogen-
icity (Calcedo and Wilson, 2013). However, the limitation
of smaller transgene capacity needs to be overcome, for
example by using minimal Schwann cell-speciﬁc promoters.
Conﬁrmation of adequate viral vector biodistribution after
intrathecal injection will also be needed in large animal
models, while the alternative route of intravenous vector
delivery should be considered (Bevan et al., 2011; Tanguy
et al., 2015). This may be also relevant since the intrathecal
injection could be difﬁcult in CMT4C patients with prom-
inent scoliosis (Kessali et al., 1997; Gabreels-Festen et al.,
1999; Azzedine et al., 2006).
In conclusion, this study provides evidence that SH3TC2
gene replacement using a Schwann cell targeted viral vector
can provide a therapeutic beneﬁt in a model of CMT4C
demyelinating neuropathy, leading to partial rescue of func-
tional, electrophysiological and morphological abnormal-
ities. Further studies are needed to optimize vector safety
and biodistribution, gene expression levels, as well as to
Figure 6 Assessment of serum NfL levels in Sh3tc2/
mice at baseline and after treatment. (A) Comparison of
serum NfL levels between untreated Sh3tc2/ and Sh3tc2 + / + lit-
termate mice showed significant elevation in the CMT4C model
both at 6 weeks of age (P = 0.0047; n = 3 mice per group), as well as
at 25 weeks of age (P = 0.0024; n = 4 Sh3tc2/ and n = 2 Sh3tc2+ / +
mice). The elevation of NfL concentration in Sh3tc2/ mice
increased significantly from 6 to 25 weeks of age (P = 0.0011),
indicating progressive axonal dysfunction in this model of demyeli-
nating neuropathy over time. In contrast, no significant progression
was found when comparing 6- to 25-week old Sh3tc2 + / + mice
(P4 0.05) (Student’s t-test for all baseline comparisons). (B)
Comparison of NfL levels in 11-week old full vector-treated (FULL,
n = 7) compared to mock vector-treated (MOCK, n = 5) Sh3tc2/
mice showed a significant reduction of NfL concentration
(P = 0.022, Mann-Whitney U-test).
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demonstrate effectiveness of this approach after the onset of
neuropathy, in order to facilitate the clinical translation for
CMT4C patients.
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